Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).

Published on Sep 1, 1997in Journal of Clinical Investigation12.28
· DOI :10.1172/JCI119628
Ele Ferrannini10
Estimated H-index: 10
Andrea Natali47
Estimated H-index: 47
+ 3 AuthorsGertrude Mingrone3
Estimated H-index: 3
Insulin resistance and insulin hypersecretion are established features of obesity. Their prevalence, however, has only been inferred from plasma insulin concentrations. We measured insulin sensitivity (as the whole-body insulin-mediated glucose uptake) and fasting posthepatic insulin delivery rate (IDR) with the use of the euglycemic insulin clamp technique in a large group of obese subjects in the database of the European Group for the Study of Insulin Resistance (1,146 nondiabetic, normotensive Caucasian men and women aged 18-85 yr, with a body mass index (BMI) ranging from 15 to 55 kg.m-2). Insulin resistance, defined as the lowest decile of insulin sensitivity in the lean subgroup (608 subjects with a mean BMI of 29 kg.m-2). Insulin sensitivity declined linearly with BMI at an age- and sex-adjusted rate of 1.2 FFM-1 per BMI unit (95% confidence intervals = 1.0-1.4). Insulin hypersecretion, defined as the upper decile of IDR, was significantly (P<0.0001) more prevalent (38%) than insulin resistance in the obese group. In the whole dataset, IDR rose as a function of both BMI and insulin resistance in a nonlinear fashion. Neither the waist circumference nor the waist-to-hip ratio, indices of body fat distribution, was related to insulin sensitivity after adjustment for age, gender, and BMI; both, however, were positively associated (P<0.001) with insulin hypersecretion, particularly in women. In nondiabetic, normotensive obese subjects, the prevalence of insulin resistance is relatively low, and is exceeded by the prevalence of insulin hypersecretion, particularly in women with central obesity. In the obese with preserved insulin sensitivity, risk for diabetes, cardiovascular risk, and response to treatment may be different than in insulin resistant obesity.
  • References (46)
  • Citations (710)
#1Manuel J. Castillo (University of Liège)H-Index: 37
#2André Scheen (University of Liège)H-Index: 70
Last.Pierre Lefebvre (University of Liège)H-Index: 44
view all 4 authors...
#1Enzo BonoraH-Index: 57
#2S. Del Prato (University of Texas Health Science Center at San Antonio)H-Index: 70
Last.Abdalmajeid Musa Alyassin (University of Texas Health Science Center at San Antonio)H-Index: 9
view all 10 authors...
Cited By710
#1Hideyoshi Kaga (Juntendo University)H-Index: 3
#2Yoshifumi Tamura (Juntendo University)H-Index: 19
Last.Satoshi Kadowaki (Juntendo University)
view all 10 authors...
#1Dylan D. Thomas (BU: Boston University)H-Index: 1
#2Barbara E. Corkey (BMC: Boston Medical Center)H-Index: 56
Last.Caroline M. Apovian (BU: Boston University)H-Index: 44
view all 4 authors...
#1Amy W. Liu (UW: University of Washington)H-Index: 1
#2Sun Ok Song (UW: University of Washington)
Last.Edward J. Boyko (UW: University of Washington)H-Index: 74
view all 8 authors...
#1Sonia M. Najjar (OU: Ohio University)H-Index: 31
#2Germán Perdomo (UBU: University of Burgos)H-Index: 13
Last.Germán Perdomo (UBU: University of Burgos)H-Index: 2
view all 3 authors...
#1Atieh Mirzababaei (Tehran University of Medical Sciences)H-Index: 1
#2Hadis Mozaffari (Tehran University of Medical Sciences)H-Index: 2
Last.Kurosh Djafarian (Tehran University of Medical Sciences)H-Index: 12
view all 5 authors...
View next paperBanting lecture 1988. Role of insulin resistance in human disease.